我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阿司匹林和抵克力得联合应用对血小板功能的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2002年第5期
页码:
402-404
栏目:
临床研究
出版日期:
2002-09-01

文章信息/Info

Title:
Effects of combination of aspirin and ticlopidine on platelet function
作者:
曹 丰; 贾国良; 郭文怡; 李成祥; 李伟杰; 栾荣华; 王小燕
第四军医大学西京医院心脏内科,陕西西安710032
Author(s):
CAO Feng; JIA Guo-liang; Guo Wen-yi; LI Cheng-xiang; LI Wei-jie; LUAN Rong-hua; WANG Xiao-yan
Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi' an,Shaanxi 710032,China
关键词:
冠状动脉疾病; 血栓; 血小板功能; 药物治疗
Keywords:
coronary disease;  thrombosis; platelet function;  drug therapy
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨阿斯匹林和抵克力得联合应用对冠心病患者冠状静脉窦血浆血小板功能的影响。方法 冠心病患者44例随机分成阿斯匹林和抵克力得联合用药试验组(24例)和单用阿斯匹林的对照组(20例),分别采集冠状静脉窦血,应用放免法测定血浆血小板α-颗粒膜蛋白(GMP-140)、血栓烷B2(TXB2)和血小板最大聚集率(MPAR)的浓度。结果 试验组冠状静脉窦血浆GMP-140,TXB2和MPAR分别为7.5±0.3μg/L、233±28 ng/L和(22±4)%,均明显高于对照组(9.9±0.5μg/L,352±46 ng/L和(28±6)%,P<05)。结论:联合应用阿司匹林和抵克力得与单用阿斯匹林比较,能更好地抑制血小板的活化。
Abstract:
AIM To assess the effects of combinative antiplatelet therapy with aspirin and ticlopidine on platelet function in the coronary circulation of the patients with coronary heart disease (CHD).METHODS 44 patients with CHD were randomized to test group(treatment with aspirin and ticlopidine )or to control group(treatment with aspirin alone).RESULTS Blood sample were obtained from the coronary sinus. The plasma levels of GMP-140,TXB2and MPAR in test group were 7.5±0.3μg/L,237±28 ng/L and (22±4)%, respectively, which were significantly lower than that of control group(9.9±0.5μg/L,352±46 ng/L and (29±6)% respectively,P<0.05)).CONCLUSION Combined antiplatelet therapy with aspirin and ticlopidine in patients with CHD is associated with a better inhibition to platelet activation than that with aspirin alone.

参考文献/References

[1] Gawaz M, Neumann FJ, Ott I,et al. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy[J].Circulation, 1996,94(3): 279-285.

[2] Wu GX, Li JY, Li PX,et al. Radioimmunoassay for the detection ofα-granule membrane protein (GMP-140) both in the human blood plasma and on the surface of the human platelets[J].Zhonghua Xueyexue Zazhi(Chin J Hematol), 1992,13(2):99-100.

[3] Li ZX. Utility radioimmunology[M]. Beijing:Scientific and Technical Documents Publishing House, 1989,198-221.

[4] Dunlop LC, Skiner MP, Bendall LJ,et al. Charactorization of GMP-140(P-selectin) as a circulating plasma protein[J].J Exp Med, 1992,175(4):1147-1155.

[5] Gregorini L, Marco J, Fajadet J,et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures[J].J Am Coll Cardiol, 1997,29:13.

[6] Stein B, Fuster V, Israel DH,et al. Platelet inhibitor agents in cardiovascular disease: an update [J].J Am Coll Cardiol,1989,14:813.

[7]刘海波,陈在嘉,高润霖,等.阿斯匹林对冠心病患者冠脉循环血小板功能及前列腺素的影响[J].中华内科杂志,1995,34(9):595-598.

[8] Albiero R, Hall P, Itoch A,et al. Results of a consecutive serises of patients receiving only antiplatelet therapy after optimized stent implantation: comparison of aspirin alone versus combined ticlopidine and aspirin therapy[J].Circulation, 1997,95:1145.

[9] Willerson JT, Golino P, Eidt J,et al. Potential usefulness of conbined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes[J].Am J Cardiol,1990,34(1):95-105.

备注/Memo

备注/Memo:
收稿日期：2001-06-25.
更新日期/Last Update: 2002-09-01